



Filovirus Research Consortium (CORC)

Building research readiness for a future filovirus outbreak

Session 2: Status of medical countermeasures development

Moderator: Dr. Simon Funnell, Ph.D.

21st January 2025



R&D Blueprint
Powering research
to prevent epidemics

Summary of species-specific vaccines with NHP preclinical efficacy data

2

Vaccine	Target Species	Antigen used	Approach	Status	Product	Comments
VSV-EBOV & Ad5-EBOV	EBOV	EBOV-Makona GP	Prime-boost	Licensed in Russia; 2015	GamEvac-Combi	Largely limited to use by Russia
Ad5-EBOV	EBOV	EBOV-Makona GP		Licensed in China; 2017		Largely limited to use by China
VSV-EBOV	EBOV	EBOV-Kikwit GP	Prime	Licensed in USA, Europe, Africa; 2019	Ervebo	In use and recommended by WHO
Ad26-EBOV & MVA-BN-filo	EBOV	Ad26: EBOV-Mayinga GP MVA: EBOV-Mayinga GP SUDV-Gulu GP MARV-Musoke GP TAFV NP	Prime-boost	Licensed in Europe, Africa; 2020	Zabdeno & Mvabea	In use and recommended by WHO
cAd3-SUDV	SUDV	not disclosed		Clinical trials, phase I		Clinical development supported by BARDA
VSV-SUDV	SUDV	SUDV-Boneface GP	Prime	Preclinical		International AIDS Vaccine Initiative
ChAdOx-biEBOV	EBOV & SUDV	EBOV-Makona GP & SUDV-Boneface GP		Clinical trials, phase I		Development ceased
VSV-BDBV	BDBV	BDBV GP	Prime	Preclinical		Currently not a priority
VSV-TAFV	TAFV	TAFV GP	Prime	Preclinical		Not a priority – only a single non-lethal human case known
VSV-MARV	MARV	MARV-Angola GP	Prime	Clinical trials, phase I		Public Health Vaccines
VSV-MARV	MARV	MARV-Musoke GP	Prime	Preclinical		International AIDS Vaccine Initiative
VSV-N4CT1-MARV	MARV	MARV-Angola GP	Prime	Preclinical		Auro Vaccines
cAd3-MARV	MARV	MARV-Angola GP	Prime & prime-boost	Clinical trials, phase I		Sabin Vaccine Institute

Agenda for this session

16:58–17:10

Overview of MCMs development and status

Brief updates on status of clinical development

- 1. MappBio**
- 2. Gilead**
- 3. Public Health Vaccines**
- 4. IAVI**
- 5. Sabin**

All speakers; Please keep to your 2-minute allocated time